The company will attend the SEN Annual Meeting with its MAP-AD® test, recently certified with the CE-IVDR mark, highlighting breakthroughs in early Alzheimer’s disease dementia prognosis.

Barcelona, November 14, 2025 – ADmit Therapeutics, a leading company in the diagnosis of neurodegenerative diseases, has confirmed its participation in the upcoming Annual Meeting of the Spanish Society of Neurology (SEN), to be held in Seville. The company will use the event to showcase the latest developments in the prediction and prognosis of Alzheimer’s Disease dementia.

The MAP-AD® Test: The Focus of Innovation

The most significant announcement is the presentation of the MAP-AD® test, recently certified with the CE-IVDR mark, a milestone that validates its quality and safety for diagnostic use within the European Union. This test is the central focus of ADmit Therapeutics’ activities at the meeting.

The company will host two informative sessions (Ágoras) exclusively dedicated to this test at the event’s Technological Hub:

  • Wednesday, November 19, 2025: from 6:00 PM to 7:00 PM.
  • Thursday, November 20, 2025: from 10:30 AM to 11:30 AM.

New Clinical Data at the Conference

In addition to the stand sessions, ADmit Therapeutics will present new validation data in the Behavior and Dementia section. The presentation is titled:

“Prediction of progression to dementia in Alzheimer’s disease: Clinical validation of a blood test independent of amyloid and tau pathology”

This session will take place on November 19 at 8:30 PM at the Barceló Sevilla Convention Center, Atrio III (Screen 8).

Visit Our Stand and Meet the Team

ADmit Therapeutics will welcome visitors at its stand, located in the Technological Hub, on November 19, 20, and 21.

Our Project Manager, Carla Trapero, and Business Development Manager, Miguel Viribay, will be present and available to discuss innovations and the future of early Alzheimer’s Disease diagnosis.

The company invites all attendees to visit its space to learn firsthand about the solutions that are redefining the prognosis of this disease.